Lefamulin acetate
Lefamulin Acetate
Lefamulin acetate (pronunciation: leh-fam-yoo-lin a-seh-tate) is a semi-synthetic pleuromutilin antibiotic developed for the treatment of community-acquired bacterial pneumonia (CABP). It is marketed under the brand name Xenleta by Nabriva Therapeutics.
Etymology
The name "Lefamulin" is derived from the class of antibiotics it belongs to, pleuromutilins, and "acetate" refers to the salt form of the drug.
Pharmacology
Lefamulin acetate works by inhibiting the synthesis of bacterial protein, which is essential for bacteria growth and reproduction. It binds to the peptidyl transferase center (PTC) on the 50S subunit of the bacterial ribosome, thereby inhibiting protein synthesis and leading to bacterial cell death.
Clinical Use
Lefamulin acetate is indicated for the treatment of adults with community-acquired bacterial pneumonia caused by susceptible isolates of designated microorganisms. It is administered either orally or intravenously.
Side Effects
Common side effects of Lefamulin acetate include diarrhea, nausea, reactions at the injection site, elevated liver enzymes, and insomnia. Serious side effects may include Clostridium difficile-associated diarrhea and QT prolongation.
Related Terms
- Pleuromutilin
- Community-acquired bacterial pneumonia
- Nabriva Therapeutics
- Ribosome
- Clostridium difficile
External links
- Medical encyclopedia article on Lefamulin acetate
- Wikipedia's article - Lefamulin acetate
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski